Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year

As of June 30 the Company had $112 in cash and cash equivalents and 71,552,402 common shares outstanding. Citius Oncology is a subsidiary of Citius Pharma. During the three months ended June 30, 2025, Citius Pharma received net proceeds from equity offerings of approximately $10.5M. “Citius Oncology is in the final stages of preparation for the U.S. commercial launch of LYMPHIR(TM),” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals (CTXR). “We successfully raised capital to support our pre-launch activities and secured distribution service agreements with leading global providers. Our launch strategy leverages cutting-edge technology and targeted marketing to reach the cutaneous T-cell lymphoma patients and providers who can benefit most from this important therapy. With launch supplies ready, distribution agreements in place, and strong engagement from key opinion leaders, we plan to make LYMPHIR available in the Q4.”